A Randomized, Multicenter, Open-label, Phase III Study of Lurbinectedin Single-Agent or Lurbinectedin in Combination With Irinotecan Versus Investigator's Choice (Topotecan or Irinotecan) in Relapsed Small Cell Lung Cancer Patients (LAGOON Trial)
Latest Information Update: 24 Jul 2024
At a glance
- Drugs Irinotecan (Primary) ; Lurbinectedin (Primary) ; Topotecan; Topotecan
- Indications Small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms LAGOON
- Sponsors PharmaMar
- 04 Jun 2024 According to PharmaMar media release, presented data from this trial at the American Society of Clinical Oncology (ASCO) meeting, which took place from 31st May to 4th June in Chicago, United States.
- 30 Apr 2024 Planned End Date changed from 1 Jun 2025 to 1 Apr 2026.
- 30 Apr 2024 Planned primary completion date changed from 1 Jun 2025 to 1 Apr 2026.